UNSPSC 51183615: Insulin lispro

This classification denotes a therapeutic insulin with the molecular formula C257H383N65O77S6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GFX7QIS1II, chemically known as insulin (ox), 8a-l-threonine-10a-l-isoleucine-30b-l-threonine- but more generally known as insulin, which bears US NIH Compound Identifier 16129672. European Medicines Agency schedules Insulin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02689MIG.

UNSPSC 51183615 Insulin lispro is a Commodity code representing rapid-acting insulin products for diabetes treatment. State and local governments procure insulin lispro primarily through cooperative purchasing vehicles that aggregate demand across multiple jurisdictions and facility types — prisons, hospitals, clinics, and public health programs. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary issuing mechanism for this category, using multi-award RFP structures that establish framework agreements with multiple qualified manufacturers to supply generic and brand-name pharmaceuticals across participating state and local entities. Vendors must certify compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), maintain relationships with authorized wholesale distributors (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson), and demonstrate pricing flexibility through flat pricing, net price formats, or WAC-minus structures. All products must meet FDA requirements, carry expiration dates of at least one year from manufacture, and maintain a minimum six-month shelf life at delivery.

MMCAP's January 2026 RFP for Generic Multi-Source Pharmaceuticals and OTC Products (S1070000015802, due March 26, 2026) covers insulin lispro as one product line within a broader pharmaceutical portfolio spanning multiple therapeutic categories distributed to participating state and local government facilities in Minnesota, Oregon, and other alliance members. The RFP weights price competitiveness at 75 percent of evaluation, with fixed pricing (10 percent), compliance with EDI capability and administrative fee formatting (5 percent each), and agreement to a 3 percent administrative fee (5 percent). Successful vendors will supply products through authorized wholesalers beginning July 1, 2026, under a two-year initial term with optional extensions at MMCAP's discretion; incumbent vendors' amendments will extend through June 30, 2028. Performance penalties ranging from $200 to $1,500 per violation apply for late reporting, missed onboarding timelines, and other compliance failures. The solicitation does not disclose specific award values or budget ranges and imposes no stated set-aside restrictions.